View ValuationCresco Labs 향후 성장Future 기준 점검 0/6Cresco Labs은 연간 수입과 매출이 각각 116.3%와 2% 증가할 것으로 예상되고 EPS는 연간 88.9%만큼 증가할 것으로 예상됩니다.핵심 정보116.3%이익 성장률88.85%EPS 성장률Pharmaceuticals 이익 성장24.0%매출 성장률2.0%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트12 Jun 2026최근 향후 성장 업데이트Breakeven Date Change • Nov 12No longer forecast to breakevenThe 8 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$13.4m in 2025.Breakeven Date Change • Sep 11No longer forecast to breakevenThe 9 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$846.2k in 2025.Breakeven Date Change • Apr 10Forecast to breakeven in 2026The 13 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 53% per year to 2025. The company is expected to make a profit of US$97.2m in 2026. Average annual earnings growth of 97% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 14Forecast to breakeven in 2025The 8 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 85% to 2024. The company is expected to make a profit of US$21.3m in 2025. Average annual earnings growth of 171% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 25No longer forecast to breakevenThe 14 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$52.0m in 2025. New consensus forecast suggests the company will make a loss of US$4.17m in 2025.공시 • Aug 17Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023Cresco Labs Inc. provided revenue guidance for the second half of 2023. For the period, the company expects total revenue to be down high single digits compared to the first half of the year.모든 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 23Cresco Labs Inc. to Report Q1, 2026 Results on May 08, 2026Cresco Labs Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026공시 • Feb 23Cresco Labs Inc. to Report Q4, 2025 Results on Mar 05, 2026Cresco Labs Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 05, 2026공시 • Jan 30Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million.Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million. Security Name: Subordinate Voting Shares Security Type: Common Stock Transaction Features: At the Market Offering공시 • Nov 06Cresco Labs Inc. Reports Unaudited Impairment Loss for the Third Quarter Ended September 30, 2025Cresco Labs Inc. reported unaudited impairment loss for the third quarter ended September 30, 2025. For the period, the company reported impairment loss of $2,365,000 against $2,320,000 a year ago. non-cash impairment charges of $2 million related to California assets being considered held for sale.공시 • Oct 22Cresco Labs Inc. to Report Q3, 2025 Results on Nov 05, 2025Cresco Labs Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025공시 • Jul 22Cresco Labs Inc., Annual General Meeting, Sep 16, 2025Cresco Labs Inc., Annual General Meeting, Sep 16, 2025.공시 • Jul 17Cresco Labs Inc. to Report Q2, 2025 Results on Aug 07, 2025Cresco Labs Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 07, 2025공시 • May 29Cresco Labs Inc. to Report Q1, 2025 Results on May 30, 2025Cresco Labs Inc. announced that they will report Q1, 2025 results on May 30, 2025공시 • Apr 29Cresco Labs Inc. to Report Q1, 2025 Results on May 09, 2025Cresco Labs Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025공시 • Mar 03Cresco Labs Inc. to Report Q4, 2024 Results on Mar 12, 2025Cresco Labs Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 12, 2025Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 12No longer forecast to breakevenThe 8 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$13.4m in 2025.Reported Earnings • Nov 10Third quarter 2024 earnings released: US$0.03 loss per share (vs US$0.34 loss in 3Q 2023)Third quarter 2024 results: US$0.03 loss per share (improved from US$0.34 loss in 3Q 2023). Revenue: US$179.8m (down 3.8% from 3Q 2023). Net loss: US$10.5m (loss narrowed 91% from 3Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.공시 • Oct 17Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024Cresco Labs Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 08, 2024공시 • Sep 29Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of DirectorsCresco Labs Inc. announced that Tarik Brooks has resigned from the Company's Board of Directors to devote his time to other interests.공시 • Sep 12Cresco Labs Inc. Announces CFO ChangesCresco Labs Inc. announced that Dennis Olis, Chief Financial Officer, will retire from Cresco Labs after a planned transition to Sharon Schuler, an experienced financial and strategy executive. Schuler recently joined Cresco Labs while preparing to take the role of Chief Financial Officer upon Olis's departure. Schuler brings an extensive corporate finance background in publicly traded wholesalers and retailers, most recently as an executive leadership team member at BJ's Wholesale Club, a membership warehouse club spanning 244 clubs and 178 gas stations, across 20 states with $20 billion in annual revenue. Olis has served as Cresco Labs CFO since July 2020. During his tenure, Cresco Labs grew from $125 million in annual revenue to more than $735 million1 today. The Company also saw significant profitability improvements with Adjusted EBITDA margin improving by 2,900 basis points and annual operating cashflow improving by over $100 million annually 2. He successfully prepared the Company for future U.S. listings through conversion to US GAAP and SOX compliance readiness. For the last three years, Schuler was responsible for planning and analysis of BJ's Wholesale Club's short and long-term financial outlook. Prior to that, she spent over 20 years in senior financial management roles for large public and private national retailers including The TJX Companies, Clarks America, and Caleres. Schuler holds an MBA in Integrated Management and a bachelor's in economics from Michigan State University.New Risk • Sep 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$172m Forecast net loss in 1 year: US$29m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$29m net loss next year). Significant insider selling over the past 3 months (€373k sold).Breakeven Date Change • Sep 11No longer forecast to breakevenThe 9 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$846.2k in 2025.New Risk • Aug 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Significant insider selling over the past 3 months (€513k sold).Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)Second quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$184.4m (down 4.8% from 2Q 2023). Net loss: US$54.3m (loss widened 49% from 2Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.공시 • Jul 23Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024Cresco Labs Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024Recent Insider Transactions • Jun 18Co-Founder & Independent Director recently sold €160k worth of stockOn the 14th of June, Robert Sampson sold around 100k shares on-market at roughly €1.60 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €891k.New Risk • Jun 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold).New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold).Recent Insider Transactions • Jun 09Co-Founder & Independent Director recently sold €84k worth of stockOn the 31st of May, Robert Sampson sold around 50k shares on-market at roughly €1.68 per share. This transaction amounted to 8.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €707k.Recent Insider Transactions • May 29Co-Founder & Independent Director recently sold €246k worth of stockOn the 24th of May, Robert Sampson sold around 131k shares on-market at roughly €1.88 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by €623k.Reported Earnings • May 19First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: US$0.015 loss per share (improved from US$0.085 loss in 1Q 2023). Revenue: US$184.3m (down 3.3% from 1Q 2023). Net loss: US$5.19m (loss narrowed 80% from 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공시 • May 17Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million on April 24, 2024. Consideration consists of a mix of initial cash consideration, deferred consideration and equity. As part of the acquisition, the Cresco Labs Inc. acquired two operating dispensaries in Pennsylvania, as well as the rights to open a new store under a third license in the future. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC on April 24, 2024.공시 • May 01Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024Cresco Labs Inc. announced that they will report Q1, 2024 results Pre-Market on May 15, 2024공시 • Apr 11Cresco Labs Inc., Annual General Meeting, Jun 10, 2024Cresco Labs Inc., Annual General Meeting, Jun 10, 2024.Breakeven Date Change • Apr 10Forecast to breakeven in 2026The 13 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 53% per year to 2025. The company is expected to make a profit of US$97.2m in 2026. Average annual earnings growth of 97% is required to achieve expected profit on schedule.New Risk • Mar 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$180m Forecast net loss in 2 years: US$22m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$22m net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).Reported Earnings • Mar 14Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)Full year 2023 results: US$0.53 loss per share (improved from US$0.71 loss in FY 2022). Revenue: US$770.9m (down 6.6% from FY 2022). Net loss: US$179.9m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Mar 14Forecast to breakeven in 2025The 8 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 85% to 2024. The company is expected to make a profit of US$21.3m in 2025. Average annual earnings growth of 171% is required to achieve expected profit on schedule.New Risk • Mar 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold).공시 • Feb 28Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024Cresco Labs Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024공시 • Feb 01Cresco Labs Inc. Promotes Greg Butler to the Position of PresidentCresco Labs Inc. announce the promotion of Greg Butler to the position of President. In this role, Butler will oversee all aspects of Cresco Labs' operations, including production, retail operations, marketing and sales, corporate planning, and investor relations. Butler joined Cresco Labs in 2020 as Chief Commercial Officer and has advised the company since 2018. He has been instrumental in innovating and professionalizing all aspects of Cresco Labs' business including strategic planning, wholesale operations, and retail expansion. Prior to Cresco Labs, Butler had over two decades of experience leading large iconic and insurgent brands for both large Fortune 500 and smaller privately owned businesses.New Risk • Jan 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold).New Risk • Dec 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)Third quarter 2023 results: US$0.34 loss per share (further deteriorated from US$0.033 loss in 3Q 2022). Revenue: US$190.6m (down 7.7% from 3Q 2022). Net loss: US$115.6m (loss widened US$105.8m from 3Q 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.공시 • Nov 02Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023Cresco Labs Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023공시 • Oct 20Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.Cresco Labs Inc. entered into a definitive agreement to acquire Sole Licensed Arizona Operation of Cresco Labs Inc. for $6.5 million on September 13, 2023. The transaction was closed following approval by the Arizona Department of Health Services. SSC Advisors acted as financial advisor to Cresco Labs Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc. on October 17, 2023.Breakeven Date Change • Sep 25No longer forecast to breakevenThe 14 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$52.0m in 2025. New consensus forecast suggests the company will make a loss of US$4.17m in 2025.New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).Recent Insider Transactions • Aug 20Chief Financial Officer recently bought €101k worth of stockOn the 17th of August, Dennis Olis bought around 100k shares on-market at roughly €1.01 per share. This transaction increased Dennis' direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months.공시 • Aug 17Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023Cresco Labs Inc. provided revenue guidance for the second half of 2023. For the period, the company expects total revenue to be down high single digits compared to the first half of the year.Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)Second quarter 2023 results: US$0.14 loss per share (further deteriorated from US$0.046 loss in 2Q 2022). Revenue: US$197.9m (down 7.2% from 2Q 2022). Net loss: US$43.5m (loss widened 221% from 2Q 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.공시 • Aug 03Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023Cresco Labs Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 16, 2023Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 25First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)First quarter 2023 results: US$0.092 loss per share. Revenue: US$194.2m (down 7.3% from 1Q 2022). Net loss: US$27.8m (loss widened 1.6% from 1Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.공시 • May 13Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023Cresco Labs Inc. announced that they will report Q1, 2023 results Pre-Market on May 24, 2023Buying Opportunity • May 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €1.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 12% in 2 years. Earnings is forecast to grow by 96% in the next 2 years.Breakeven Date Change • Apr 21Forecast breakeven date moved forward to 2024The 13 analysts covering Cresco Labs previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 70% to 2023. The company is expected to make a profit of US$12.8m in 2024. Average annual earnings growth of 120% is required to achieve expected profit on schedule.Buying Opportunity • Apr 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €1.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 0.7% in a year. Earnings is forecast to grow by 78% in the next year.Recent Insider Transactions • Apr 03Insider recently sold €105k worth of stockOn the 29th of March, Dominic Sergi sold around 100k shares on-market at roughly €1.05 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €106k. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months.Recent Insider Transactions • Mar 29Insider recently sold €106k worth of stockOn the 23rd of March, Dominic Sergi sold around 100k shares on-market at roughly €1.06 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months.Reported Earnings • Mar 17Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)Full year 2022 results: US$0.71 loss per share (improved from US$1.22 loss in FY 2021). Revenue: US$842.7m (up 4.6% from FY 2021). Net loss: US$215.1m (loss narrowed 33% from FY 2021). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Dec 04Co-Founder & Independent Director recently sold €1.2m worth of stockOn the 1st of December, Robert Sampson sold around 383k shares on-market at roughly €3.15 per share. This transaction amounted to 62% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.Breakeven Date Change • Dec 03Forecast breakeven date moved forward to 2023The 19 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 86% to 2022. The company is expected to make a profit of US$3.08m in 2023. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 22Forecast breakeven date pushed back to 2024The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% per year to 2023. The company is expected to make a profit of US$60.8m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)Third quarter 2022 results: US$0.011 loss per share (improved from US$1.00 loss in 3Q 2021). Revenue: US$210.5m (down 1.1% from 3Q 2021). Net loss: US$3.25m (loss narrowed 99% from 3Q 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Breakeven Date Change • Oct 25No longer forecast to breakevenThe 18 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$19.0m in 2023. New consensus forecast suggests the company will make a loss of US$11.1m in 2024.Reported Earnings • Aug 19Second quarter 2022 earnings released: US$0.028 loss per share (vs US$0.019 loss in 2Q 2021)Second quarter 2022 results: US$0.028 loss per share (down from US$0.019 loss in 2Q 2021). Revenue: US$218.2m (up 6.2% from 2Q 2021). Net loss: US$8.30m (loss widened 72% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Board Change • Aug 19High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Jul 20Forecast breakeven date moved forward to 2022The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$1.62m in 2022. Earnings growth of 64% is required to achieve expected profit on schedule.Recent Insider Transactions • May 27Chief Financial Officer recently bought €75k worth of stockOn the 24th of May, Dennis Olis bought around 24k shares on-market at roughly €3.12 per share. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months.Breakeven Date Change • May 19Forecast breakeven date pushed back to 2023The 16 analysts covering Cresco Labs previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 97% to 2022. The company is expected to make a profit of US$100.4m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • May 19First quarter 2022 earnings released: US$0.081 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.081 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$214.4m (up 23% from 1Q 2021). Net loss: US$23.7m (loss narrowed 20% from 1Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 6.6% growth forecast for the industry in Germany.Breakeven Date Change • May 11Forecast breakeven date moved forward to 2022The 17 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$34.9m in 2022. Earnings growth of 82% is required to achieve expected profit on schedule.공시 • May 07Cresco Labs Inc. to Report Q1, 2022 Results on May 18, 2022Cresco Labs Inc. announced that they will report Q1, 2022 results Pre-Market on May 18, 2022Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 24Cresco Labs Inc., Annual General Meeting, Jun 30, 2022Cresco Labs Inc., Annual General Meeting, Jun 30, 2022.공시 • Apr 14Cresco Labs Inc. Launches Floracal Farms Brand to IllinoisCresco Labs announced the launch of its premium craft brand FloraCal Farms, which features unique genetics in curated flower, live rosin vape and live rosin concentrate formats now available at all Illinois Sunnyside stores and other retailers ahead of the 420 cannabis holiday. Born in Sonoma County, FloraCal Farms continues to honor its California heritage through a commitment to tailored craftsmanship established by wife-and-husband founders Karen and Drew Duval, who oversee commercial sales and cultivation at the Company. FloraCal Farms maintains a rigorous pheno-hunting process that starts with hundreds of plants, then hand-selects only the winning strains to be developed into flower, vapes and hand-crafted concentrates. Flower is always hand-harvested, trimmed and packaged to preserve delicate flower characteristics. Live rosin vapes and concentrates follow solventless extraction processes, an innovative method new to Cresco Labs’ wholesale portfolio that removes the oil containing components from the raw materials simply through ice water and manual agitation – without the use of chemical solvents. The resulting materials are pressed to produce live rosin bursting with the terpenes, flavor and potency that cannabis connoisseurs enjoy. Available for sale forms at launch in Illinois include hand-trimmed flower (3.5g), live rosin vape cartridges (500mg) and live rosin badder concentrates (1g). More products and exclusive strains will arrive on dispensary shelves throughout the year. The launch of FloraCal Farms in Illinois rounds out the Company’s wholesale portfolio in Illinois. Other available brands include Cresco, High Supply, Good News, Mindy’s, Wonder Wellness and Remedi.Buying Opportunity • Mar 04Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be US$7.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% per annum over the last 3 years. The company became loss making over the last 3 years.공시 • Jan 30Cresco Labs Announces Launch of Khalifa Kush Products at Cookies Dispensaries Throughout CaliforniaCresco Labs announced flower and pre-rolls from Khalifa Kush are available for sale at Cookies stores throughout California. Cresco Labs has an exclusive cultivation and product collaboration agreement with multi-platinum-selling, GRAMMY® and Golden Globe® Award-nominated recording artist Wiz Khalifa’s cannabis brand. Through the partnership, the Company’s FloraCal Farms and Continuum distribution platform will be the sole producer and distributor, respectively, of premium branded products featuring Khalifa Kush’s signature “KK” strain in California. An expanded line is expected to arrive at additional retail partners throughout the year.공시 • Dec 12Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Laurel Harvest Labs, LLC for $80 million on October 14, 2021. The transaction will include a newly constructed indoor cultivation facility in Lancaster County allowing for new cultivation capacity, the foundation to expand the facility further, and another strategic point of distribution that is complementary to Cresco Labs’ cultivation facility in Brookville. As part of the acquisition, Cresco Labs will also acquire the real estate of Laurel Harvest’s cultivation facility and Scranton dispensary. The purchase price would be payable upon closing of the transaction, subject to the adjustments and lock-up agreements contained in the definitive agreements. Purchase price comprised of a mix of cash and stock, plus earnout amounts payable upon achievement of certain post-closing milestones. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The transaction is subject to, among other things, the approval and receipt of all required CSE, regulatory and court approvals. The transaction is expected to close in Q4 of 2021. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million on December 10, 2021. John Jones, Joan C. Arnold, Agustin E. Rodriguez, Mamta K. Shah, Julia E. Tomec, Joseph Walsh, Kimberly Hughes Gillespie, and John J. McGrath III from Troutman Pepper Hamilton Sanders LLP acted as a legal advisor to Laurel Harvest Labs.공시 • Nov 27Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC on November 25, 2021.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.79 loss per share (vs US$0.035 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$215.5m (up 45% from 3Q 2020). Net loss: US$263.5m (loss widened US$256.0m from 3Q 2020).공시 • Sep 24Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 18 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$129.6m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule.공시 • Sep 04Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for approximately $160 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. As of May 3, 2021, Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in respect to Cresco Labs’ pending acquisition of Cultivate Licensing LLC and BL Real Estate LLC got expired. The Transaction remains subject to certain closing conditions, including approval from the Commonwealth of Massachusetts which is anticipated to be received in the fourth quarter of 2021. The transaction is expected to close in the fourth quarter of 2021. Erica Rice, Jesse Harlan Alderman, Christopher "Kip" Cawley, Teresa A. Martland, Jonathan A. Keselenko, Joshua S. Jarvis, Stacie S. Aarestad and Ryan M. Rourke Reed of Foley Hoag LLP acted as legal advisor to Cultivate Holdings. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC on September 3, 2021.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Breakeven Date Change • Aug 18Forecast breakeven pushed back to 2022The 16 analysts covering Cresco Labs previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 99% to 2021. The company is expected to make a profit of US$131.8m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule.공시 • Aug 18Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC on August 17, 2021. The consideration will be satisfied through the payment of cash and a twenty-four (24) month promissory note. The Transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The cash consideration would be payable upon closing of the Transaction. The Transaction implies a 1.8x 2021 revenue multiple. Blair Wellness team will join Cresco Family. The closing of the Transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Acquisition is expected to be immediately accretive.Reported Earnings • Aug 14Second quarter 2021 earnings releasedThe company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$210.0m (up 129% from 2Q 2020). Net loss: US$4.83m (loss narrowed 75% from 2Q 2020).Board Change • Aug 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Sidney Dillard was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Aug 04Insider recently sold €3.6m worth of stockOn the 26th of July, Dominic Sergi sold around 425k shares on-market at roughly €8.42 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €20m more than they bought in the last 12 months.공시 • May 28Cresco Labs Inc. Provides Earnings Guidance for the Year 2021Cresco Labs Inc. provided earnings guidance for the year 2021. For the year, the company expects annualized revenue run-rate of more than $1 billion by the end of 2021.Reported Earnings • Mar 27Full year 2020 earnings released: US$0.17 loss per share (vs US$0.36 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$476.3m (up 284% from FY 2019). Net loss: US$36.6m (loss narrowed 15% from FY 2019).공시 • Mar 20Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in the fourth quarter of 2021.공시 • Mar 05Cresco Labs Inc. to Report Q4, 2020 Results on Mar 25, 2021Cresco Labs Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 25, 2021공시 • Feb 18Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations.Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations on February 16, 2021. These acquisitions give Cresco Labs Inc. four additional dispensaries, bringing Cresco Labs Inc. dispensary presence in Ohio to five. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Four dispensaries of Verdant Creations on February 16, 2021.공시 • Feb 10Cresco Labs Signs Exclusive Distribution Agreement with California Cannabis Producer, Emerald Family FarmsCresco Labs announced that it has entered into an exclusive distribution agreement with Emerald Family Farms. The Agreement will bring EFF’s award-winning lineup of jarred flower, pre-rolls and concentrates onto Cresco’s California distribution platform. This Agreement continues to build on that strength with some of the best flower in California being added to company roster of top performing California brands. Having brought hundreds of the region’s finest farmers under one banner, EFF’s success story is proof that exceptional cannabis and uncompromising values can coexist.공시 • Feb 02+ 1 more updateCresco Labs Appoints Ty Gent as the New Chief Operating OfficerCresco Labs announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer. As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling. Gent joins Cresco with more than 35 years of CPG and supply chain leadership experience. Most recently, he was the Chief Supply Chain Officer at US Foods, where he developed and implemented a new supply chain strategy, optimized its large-scale transportation network, launched field-based continuous improvement processes, and upgraded key systems technologies and planning capabilities. As a subject matter expert in supply chain optimization, S&OP planning, anufacturing, warehouse management, distribution, and quality and safety, Gent brings expertise that is directly transferrable to Cresco’s key focus of producing and distributing branded products at substantial scale.Recent Insider Transactions • Jan 30Insider recently sold €2.7m worth of stockOn the 28th of January, Joseph Caltabiano sold around 334k shares on-market at roughly €8.21 per share. In the last 3 months, they made an even bigger sale worth €3.2m. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.이익 및 매출 성장 예측DB:6CQ - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028676N/A3772212/31/2027670-94479512/31/2026654-4294263/31/2026641-134-437N/A12/31/2025656-1353573N/A9/30/2025673-524475N/A6/30/2025688-4688118N/A3/31/2025708-84103126N/A12/31/2024724-74109132N/A9/30/2024733-6775100N/A6/30/2024741-1725991N/A3/31/2024747-1554892N/A12/31/2023756-176159N/A9/30/2023767-339-165N/A6/30/2023786-234-2350N/A3/31/2023806-211-4425N/A12/31/2022825-212-6719N/A9/30/2022842-65-3853N/A6/30/2022848-326-6234N/A3/31/2022841-318-114-2N/A12/31/2021806-320-8314N/A9/30/2021750-360-99-3N/A6/30/2021687-73-7420N/A3/31/2021573-105-2543N/A12/31/2020463-102-97-8N/A9/30/2020345-76-149-34N/A6/30/2020231-98-186-70N/A3/31/2020168-64-185-57N/A12/31/2019124-43N/A-25N/A9/30/2019101-20N/A-29N/A6/30/201978-14N/A-20N/A3/31/201957-12N/A-16N/A12/31/201841-2N/A-10N/A9/30/2018280N/A-4N/A6/30/2018191N/A-7N/A3/31/2018131N/A-6N/A12/31/201710-3N/A-5N/A12/31/20163-8N/A-11N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6CQ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 6CQ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 6CQ 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 6CQ 의 수익(연간 2%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 6CQ 의 수익(연간 2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6CQ의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/11 19:48종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cresco Labs Inc.는 11명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkLuke HannanCanaccord Genuity8명의 분석가 더 보기
Breakeven Date Change • Nov 12No longer forecast to breakevenThe 8 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$13.4m in 2025.
Breakeven Date Change • Sep 11No longer forecast to breakevenThe 9 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$846.2k in 2025.
Breakeven Date Change • Apr 10Forecast to breakeven in 2026The 13 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 53% per year to 2025. The company is expected to make a profit of US$97.2m in 2026. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 14Forecast to breakeven in 2025The 8 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 85% to 2024. The company is expected to make a profit of US$21.3m in 2025. Average annual earnings growth of 171% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 25No longer forecast to breakevenThe 14 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$52.0m in 2025. New consensus forecast suggests the company will make a loss of US$4.17m in 2025.
공시 • Aug 17Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023Cresco Labs Inc. provided revenue guidance for the second half of 2023. For the period, the company expects total revenue to be down high single digits compared to the first half of the year.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 23Cresco Labs Inc. to Report Q1, 2026 Results on May 08, 2026Cresco Labs Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
공시 • Feb 23Cresco Labs Inc. to Report Q4, 2025 Results on Mar 05, 2026Cresco Labs Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 05, 2026
공시 • Jan 30Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million.Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million. Security Name: Subordinate Voting Shares Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Nov 06Cresco Labs Inc. Reports Unaudited Impairment Loss for the Third Quarter Ended September 30, 2025Cresco Labs Inc. reported unaudited impairment loss for the third quarter ended September 30, 2025. For the period, the company reported impairment loss of $2,365,000 against $2,320,000 a year ago. non-cash impairment charges of $2 million related to California assets being considered held for sale.
공시 • Oct 22Cresco Labs Inc. to Report Q3, 2025 Results on Nov 05, 2025Cresco Labs Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025
공시 • Jul 22Cresco Labs Inc., Annual General Meeting, Sep 16, 2025Cresco Labs Inc., Annual General Meeting, Sep 16, 2025.
공시 • Jul 17Cresco Labs Inc. to Report Q2, 2025 Results on Aug 07, 2025Cresco Labs Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 07, 2025
공시 • May 29Cresco Labs Inc. to Report Q1, 2025 Results on May 30, 2025Cresco Labs Inc. announced that they will report Q1, 2025 results on May 30, 2025
공시 • Apr 29Cresco Labs Inc. to Report Q1, 2025 Results on May 09, 2025Cresco Labs Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025
공시 • Mar 03Cresco Labs Inc. to Report Q4, 2024 Results on Mar 12, 2025Cresco Labs Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 12, 2025
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 12No longer forecast to breakevenThe 8 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$13.4m in 2025.
Reported Earnings • Nov 10Third quarter 2024 earnings released: US$0.03 loss per share (vs US$0.34 loss in 3Q 2023)Third quarter 2024 results: US$0.03 loss per share (improved from US$0.34 loss in 3Q 2023). Revenue: US$179.8m (down 3.8% from 3Q 2023). Net loss: US$10.5m (loss narrowed 91% from 3Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
공시 • Oct 17Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024Cresco Labs Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 08, 2024
공시 • Sep 29Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of DirectorsCresco Labs Inc. announced that Tarik Brooks has resigned from the Company's Board of Directors to devote his time to other interests.
공시 • Sep 12Cresco Labs Inc. Announces CFO ChangesCresco Labs Inc. announced that Dennis Olis, Chief Financial Officer, will retire from Cresco Labs after a planned transition to Sharon Schuler, an experienced financial and strategy executive. Schuler recently joined Cresco Labs while preparing to take the role of Chief Financial Officer upon Olis's departure. Schuler brings an extensive corporate finance background in publicly traded wholesalers and retailers, most recently as an executive leadership team member at BJ's Wholesale Club, a membership warehouse club spanning 244 clubs and 178 gas stations, across 20 states with $20 billion in annual revenue. Olis has served as Cresco Labs CFO since July 2020. During his tenure, Cresco Labs grew from $125 million in annual revenue to more than $735 million1 today. The Company also saw significant profitability improvements with Adjusted EBITDA margin improving by 2,900 basis points and annual operating cashflow improving by over $100 million annually 2. He successfully prepared the Company for future U.S. listings through conversion to US GAAP and SOX compliance readiness. For the last three years, Schuler was responsible for planning and analysis of BJ's Wholesale Club's short and long-term financial outlook. Prior to that, she spent over 20 years in senior financial management roles for large public and private national retailers including The TJX Companies, Clarks America, and Caleres. Schuler holds an MBA in Integrated Management and a bachelor's in economics from Michigan State University.
New Risk • Sep 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$172m Forecast net loss in 1 year: US$29m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$29m net loss next year). Significant insider selling over the past 3 months (€373k sold).
Breakeven Date Change • Sep 11No longer forecast to breakevenThe 9 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$846.2k in 2025.
New Risk • Aug 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Significant insider selling over the past 3 months (€513k sold).
Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)Second quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$184.4m (down 4.8% from 2Q 2023). Net loss: US$54.3m (loss widened 49% from 2Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
공시 • Jul 23Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024Cresco Labs Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024
Recent Insider Transactions • Jun 18Co-Founder & Independent Director recently sold €160k worth of stockOn the 14th of June, Robert Sampson sold around 100k shares on-market at roughly €1.60 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €891k.
New Risk • Jun 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold).
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold).
Recent Insider Transactions • Jun 09Co-Founder & Independent Director recently sold €84k worth of stockOn the 31st of May, Robert Sampson sold around 50k shares on-market at roughly €1.68 per share. This transaction amounted to 8.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €707k.
Recent Insider Transactions • May 29Co-Founder & Independent Director recently sold €246k worth of stockOn the 24th of May, Robert Sampson sold around 131k shares on-market at roughly €1.88 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by €623k.
Reported Earnings • May 19First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: US$0.015 loss per share (improved from US$0.085 loss in 1Q 2023). Revenue: US$184.3m (down 3.3% from 1Q 2023). Net loss: US$5.19m (loss narrowed 80% from 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공시 • May 17Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million on April 24, 2024. Consideration consists of a mix of initial cash consideration, deferred consideration and equity. As part of the acquisition, the Cresco Labs Inc. acquired two operating dispensaries in Pennsylvania, as well as the rights to open a new store under a third license in the future. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC on April 24, 2024.
공시 • May 01Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024Cresco Labs Inc. announced that they will report Q1, 2024 results Pre-Market on May 15, 2024
공시 • Apr 11Cresco Labs Inc., Annual General Meeting, Jun 10, 2024Cresco Labs Inc., Annual General Meeting, Jun 10, 2024.
Breakeven Date Change • Apr 10Forecast to breakeven in 2026The 13 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 53% per year to 2025. The company is expected to make a profit of US$97.2m in 2026. Average annual earnings growth of 97% is required to achieve expected profit on schedule.
New Risk • Mar 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$180m Forecast net loss in 2 years: US$22m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$22m net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
Reported Earnings • Mar 14Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)Full year 2023 results: US$0.53 loss per share (improved from US$0.71 loss in FY 2022). Revenue: US$770.9m (down 6.6% from FY 2022). Net loss: US$179.9m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Mar 14Forecast to breakeven in 2025The 8 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 85% to 2024. The company is expected to make a profit of US$21.3m in 2025. Average annual earnings growth of 171% is required to achieve expected profit on schedule.
New Risk • Mar 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold).
공시 • Feb 28Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024Cresco Labs Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024
공시 • Feb 01Cresco Labs Inc. Promotes Greg Butler to the Position of PresidentCresco Labs Inc. announce the promotion of Greg Butler to the position of President. In this role, Butler will oversee all aspects of Cresco Labs' operations, including production, retail operations, marketing and sales, corporate planning, and investor relations. Butler joined Cresco Labs in 2020 as Chief Commercial Officer and has advised the company since 2018. He has been instrumental in innovating and professionalizing all aspects of Cresco Labs' business including strategic planning, wholesale operations, and retail expansion. Prior to Cresco Labs, Butler had over two decades of experience leading large iconic and insurgent brands for both large Fortune 500 and smaller privately owned businesses.
New Risk • Jan 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold).
New Risk • Dec 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)Third quarter 2023 results: US$0.34 loss per share (further deteriorated from US$0.033 loss in 3Q 2022). Revenue: US$190.6m (down 7.7% from 3Q 2022). Net loss: US$115.6m (loss widened US$105.8m from 3Q 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings.
공시 • Nov 02Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023Cresco Labs Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023
공시 • Oct 20Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.Cresco Labs Inc. entered into a definitive agreement to acquire Sole Licensed Arizona Operation of Cresco Labs Inc. for $6.5 million on September 13, 2023. The transaction was closed following approval by the Arizona Department of Health Services. SSC Advisors acted as financial advisor to Cresco Labs Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc. on October 17, 2023.
Breakeven Date Change • Sep 25No longer forecast to breakevenThe 14 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$52.0m in 2025. New consensus forecast suggests the company will make a loss of US$4.17m in 2025.
New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Shareholders have been diluted in the past year (8.0% increase in shares outstanding).
Recent Insider Transactions • Aug 20Chief Financial Officer recently bought €101k worth of stockOn the 17th of August, Dennis Olis bought around 100k shares on-market at roughly €1.01 per share. This transaction increased Dennis' direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months.
공시 • Aug 17Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023Cresco Labs Inc. provided revenue guidance for the second half of 2023. For the period, the company expects total revenue to be down high single digits compared to the first half of the year.
Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)Second quarter 2023 results: US$0.14 loss per share (further deteriorated from US$0.046 loss in 2Q 2022). Revenue: US$197.9m (down 7.2% from 2Q 2022). Net loss: US$43.5m (loss widened 221% from 2Q 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
공시 • Aug 03Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023Cresco Labs Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 16, 2023
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 25First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)First quarter 2023 results: US$0.092 loss per share. Revenue: US$194.2m (down 7.3% from 1Q 2022). Net loss: US$27.8m (loss widened 1.6% from 1Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.
공시 • May 13Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023Cresco Labs Inc. announced that they will report Q1, 2023 results Pre-Market on May 24, 2023
Buying Opportunity • May 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €1.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 12% in 2 years. Earnings is forecast to grow by 96% in the next 2 years.
Breakeven Date Change • Apr 21Forecast breakeven date moved forward to 2024The 13 analysts covering Cresco Labs previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 70% to 2023. The company is expected to make a profit of US$12.8m in 2024. Average annual earnings growth of 120% is required to achieve expected profit on schedule.
Buying Opportunity • Apr 18Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €1.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 0.7% in a year. Earnings is forecast to grow by 78% in the next year.
Recent Insider Transactions • Apr 03Insider recently sold €105k worth of stockOn the 29th of March, Dominic Sergi sold around 100k shares on-market at roughly €1.05 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €106k. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 29Insider recently sold €106k worth of stockOn the 23rd of March, Dominic Sergi sold around 100k shares on-market at roughly €1.06 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months.
Reported Earnings • Mar 17Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)Full year 2022 results: US$0.71 loss per share (improved from US$1.22 loss in FY 2021). Revenue: US$842.7m (up 4.6% from FY 2021). Net loss: US$215.1m (loss narrowed 33% from FY 2021). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Dec 04Co-Founder & Independent Director recently sold €1.2m worth of stockOn the 1st of December, Robert Sampson sold around 383k shares on-market at roughly €3.15 per share. This transaction amounted to 62% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.
Breakeven Date Change • Dec 03Forecast breakeven date moved forward to 2023The 19 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 86% to 2022. The company is expected to make a profit of US$3.08m in 2023. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 22Forecast breakeven date pushed back to 2024The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% per year to 2023. The company is expected to make a profit of US$60.8m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)Third quarter 2022 results: US$0.011 loss per share (improved from US$1.00 loss in 3Q 2021). Revenue: US$210.5m (down 1.1% from 3Q 2021). Net loss: US$3.25m (loss narrowed 99% from 3Q 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • Oct 25No longer forecast to breakevenThe 18 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$19.0m in 2023. New consensus forecast suggests the company will make a loss of US$11.1m in 2024.
Reported Earnings • Aug 19Second quarter 2022 earnings released: US$0.028 loss per share (vs US$0.019 loss in 2Q 2021)Second quarter 2022 results: US$0.028 loss per share (down from US$0.019 loss in 2Q 2021). Revenue: US$218.2m (up 6.2% from 2Q 2021). Net loss: US$8.30m (loss widened 72% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Board Change • Aug 19High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Jul 20Forecast breakeven date moved forward to 2022The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$1.62m in 2022. Earnings growth of 64% is required to achieve expected profit on schedule.
Recent Insider Transactions • May 27Chief Financial Officer recently bought €75k worth of stockOn the 24th of May, Dennis Olis bought around 24k shares on-market at roughly €3.12 per share. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months.
Breakeven Date Change • May 19Forecast breakeven date pushed back to 2023The 16 analysts covering Cresco Labs previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 97% to 2022. The company is expected to make a profit of US$100.4m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • May 19First quarter 2022 earnings released: US$0.081 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.081 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$214.4m (up 23% from 1Q 2021). Net loss: US$23.7m (loss narrowed 20% from 1Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 6.6% growth forecast for the industry in Germany.
Breakeven Date Change • May 11Forecast breakeven date moved forward to 2022The 17 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$34.9m in 2022. Earnings growth of 82% is required to achieve expected profit on schedule.
공시 • May 07Cresco Labs Inc. to Report Q1, 2022 Results on May 18, 2022Cresco Labs Inc. announced that they will report Q1, 2022 results Pre-Market on May 18, 2022
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 24Cresco Labs Inc., Annual General Meeting, Jun 30, 2022Cresco Labs Inc., Annual General Meeting, Jun 30, 2022.
공시 • Apr 14Cresco Labs Inc. Launches Floracal Farms Brand to IllinoisCresco Labs announced the launch of its premium craft brand FloraCal Farms, which features unique genetics in curated flower, live rosin vape and live rosin concentrate formats now available at all Illinois Sunnyside stores and other retailers ahead of the 420 cannabis holiday. Born in Sonoma County, FloraCal Farms continues to honor its California heritage through a commitment to tailored craftsmanship established by wife-and-husband founders Karen and Drew Duval, who oversee commercial sales and cultivation at the Company. FloraCal Farms maintains a rigorous pheno-hunting process that starts with hundreds of plants, then hand-selects only the winning strains to be developed into flower, vapes and hand-crafted concentrates. Flower is always hand-harvested, trimmed and packaged to preserve delicate flower characteristics. Live rosin vapes and concentrates follow solventless extraction processes, an innovative method new to Cresco Labs’ wholesale portfolio that removes the oil containing components from the raw materials simply through ice water and manual agitation – without the use of chemical solvents. The resulting materials are pressed to produce live rosin bursting with the terpenes, flavor and potency that cannabis connoisseurs enjoy. Available for sale forms at launch in Illinois include hand-trimmed flower (3.5g), live rosin vape cartridges (500mg) and live rosin badder concentrates (1g). More products and exclusive strains will arrive on dispensary shelves throughout the year. The launch of FloraCal Farms in Illinois rounds out the Company’s wholesale portfolio in Illinois. Other available brands include Cresco, High Supply, Good News, Mindy’s, Wonder Wellness and Remedi.
Buying Opportunity • Mar 04Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be US$7.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% per annum over the last 3 years. The company became loss making over the last 3 years.
공시 • Jan 30Cresco Labs Announces Launch of Khalifa Kush Products at Cookies Dispensaries Throughout CaliforniaCresco Labs announced flower and pre-rolls from Khalifa Kush are available for sale at Cookies stores throughout California. Cresco Labs has an exclusive cultivation and product collaboration agreement with multi-platinum-selling, GRAMMY® and Golden Globe® Award-nominated recording artist Wiz Khalifa’s cannabis brand. Through the partnership, the Company’s FloraCal Farms and Continuum distribution platform will be the sole producer and distributor, respectively, of premium branded products featuring Khalifa Kush’s signature “KK” strain in California. An expanded line is expected to arrive at additional retail partners throughout the year.
공시 • Dec 12Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Laurel Harvest Labs, LLC for $80 million on October 14, 2021. The transaction will include a newly constructed indoor cultivation facility in Lancaster County allowing for new cultivation capacity, the foundation to expand the facility further, and another strategic point of distribution that is complementary to Cresco Labs’ cultivation facility in Brookville. As part of the acquisition, Cresco Labs will also acquire the real estate of Laurel Harvest’s cultivation facility and Scranton dispensary. The purchase price would be payable upon closing of the transaction, subject to the adjustments and lock-up agreements contained in the definitive agreements. Purchase price comprised of a mix of cash and stock, plus earnout amounts payable upon achievement of certain post-closing milestones. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The transaction is subject to, among other things, the approval and receipt of all required CSE, regulatory and court approvals. The transaction is expected to close in Q4 of 2021. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million on December 10, 2021. John Jones, Joan C. Arnold, Agustin E. Rodriguez, Mamta K. Shah, Julia E. Tomec, Joseph Walsh, Kimberly Hughes Gillespie, and John J. McGrath III from Troutman Pepper Hamilton Sanders LLP acted as a legal advisor to Laurel Harvest Labs.
공시 • Nov 27Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC on November 25, 2021.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.79 loss per share (vs US$0.035 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$215.5m (up 45% from 3Q 2020). Net loss: US$263.5m (loss widened US$256.0m from 3Q 2020).
공시 • Sep 24Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 18 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$129.6m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule.
공시 • Sep 04Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for approximately $160 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. As of May 3, 2021, Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in respect to Cresco Labs’ pending acquisition of Cultivate Licensing LLC and BL Real Estate LLC got expired. The Transaction remains subject to certain closing conditions, including approval from the Commonwealth of Massachusetts which is anticipated to be received in the fourth quarter of 2021. The transaction is expected to close in the fourth quarter of 2021. Erica Rice, Jesse Harlan Alderman, Christopher "Kip" Cawley, Teresa A. Martland, Jonathan A. Keselenko, Joshua S. Jarvis, Stacie S. Aarestad and Ryan M. Rourke Reed of Foley Hoag LLP acted as legal advisor to Cultivate Holdings. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC on September 3, 2021.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Breakeven Date Change • Aug 18Forecast breakeven pushed back to 2022The 16 analysts covering Cresco Labs previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 99% to 2021. The company is expected to make a profit of US$131.8m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule.
공시 • Aug 18Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC on August 17, 2021. The consideration will be satisfied through the payment of cash and a twenty-four (24) month promissory note. The Transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The cash consideration would be payable upon closing of the Transaction. The Transaction implies a 1.8x 2021 revenue multiple. Blair Wellness team will join Cresco Family. The closing of the Transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Acquisition is expected to be immediately accretive.
Reported Earnings • Aug 14Second quarter 2021 earnings releasedThe company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$210.0m (up 129% from 2Q 2020). Net loss: US$4.83m (loss narrowed 75% from 2Q 2020).
Board Change • Aug 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Sidney Dillard was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Aug 04Insider recently sold €3.6m worth of stockOn the 26th of July, Dominic Sergi sold around 425k shares on-market at roughly €8.42 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €20m more than they bought in the last 12 months.
공시 • May 28Cresco Labs Inc. Provides Earnings Guidance for the Year 2021Cresco Labs Inc. provided earnings guidance for the year 2021. For the year, the company expects annualized revenue run-rate of more than $1 billion by the end of 2021.
Reported Earnings • Mar 27Full year 2020 earnings released: US$0.17 loss per share (vs US$0.36 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$476.3m (up 284% from FY 2019). Net loss: US$36.6m (loss narrowed 15% from FY 2019).
공시 • Mar 20Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million.Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in the fourth quarter of 2021.
공시 • Mar 05Cresco Labs Inc. to Report Q4, 2020 Results on Mar 25, 2021Cresco Labs Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 25, 2021
공시 • Feb 18Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations.Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations on February 16, 2021. These acquisitions give Cresco Labs Inc. four additional dispensaries, bringing Cresco Labs Inc. dispensary presence in Ohio to five. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Four dispensaries of Verdant Creations on February 16, 2021.
공시 • Feb 10Cresco Labs Signs Exclusive Distribution Agreement with California Cannabis Producer, Emerald Family FarmsCresco Labs announced that it has entered into an exclusive distribution agreement with Emerald Family Farms. The Agreement will bring EFF’s award-winning lineup of jarred flower, pre-rolls and concentrates onto Cresco’s California distribution platform. This Agreement continues to build on that strength with some of the best flower in California being added to company roster of top performing California brands. Having brought hundreds of the region’s finest farmers under one banner, EFF’s success story is proof that exceptional cannabis and uncompromising values can coexist.
공시 • Feb 02+ 1 more updateCresco Labs Appoints Ty Gent as the New Chief Operating OfficerCresco Labs announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer. As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling. Gent joins Cresco with more than 35 years of CPG and supply chain leadership experience. Most recently, he was the Chief Supply Chain Officer at US Foods, where he developed and implemented a new supply chain strategy, optimized its large-scale transportation network, launched field-based continuous improvement processes, and upgraded key systems technologies and planning capabilities. As a subject matter expert in supply chain optimization, S&OP planning, anufacturing, warehouse management, distribution, and quality and safety, Gent brings expertise that is directly transferrable to Cresco’s key focus of producing and distributing branded products at substantial scale.
Recent Insider Transactions • Jan 30Insider recently sold €2.7m worth of stockOn the 28th of January, Joseph Caltabiano sold around 334k shares on-market at roughly €8.21 per share. In the last 3 months, they made an even bigger sale worth €3.2m. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.